Limitations of CD95 ligand-transduced killer dendritic cells to prevent graft rejections

Experimental Dermatology

Volumn 14, Issue 4, 2005, Pages 273-280

  Kusuhara, Masahiro ^a,b   Matsue, Hiroyuki ^a,c  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Apoptosis; Dendritic cell; Graft rejection; Suppression

Indexed keywords

FAS LIGAND;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CELL ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG MECHANISM; FEMALE; GENETIC TRANSDUCTION; GRAFT REJECTION; GRAFT SURVIVAL; IN VITRO STUDY; IN VIVO STUDY; KILLER CELL; LYMPHOCYTE ACTIVATION; MOUSE; MOUSE STRAIN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; RECIPIENT; SKIN ALLOGRAFT; SKIN TRANSPLANTATION; T CELL DEPLETION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CELL TRANSPLANTATION; DENDRITIC CELLS; FAS LIGAND PROTEIN; GRAFT REJECTION; IMMUNE SYSTEM; IMMUNE TOLERANCE; ISOANTIGENS; KILLER CELLS, NATURAL; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; SKIN; SKIN TRANSPLANTATION; T-LYMPHOCYTES; THYMIDINE;

EID: 16844364856     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0906-6705.2005.00307.x     Document Type: Article

References (40)

1. Banchereau J, Steinman R M. Dendritic cells and the control of immunity. Nature 1998: 392: 245-252.
2. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000: 18: 767-811.
3. Fong L, Engleman E G. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000: 18: 245-273.
4. Dallal R M, Lotze M T. The dendritic cell and human cancer vaccines. Curr Opin Immunol 2000: 12: 583-588.
5. Cerundolo V, Hermans I F, Salio M. Dendritic cells: a journey from laboratory to clinic. Nat Immunol 2004: 5: 7-10.
6. Steinman R M, Hawiger D, Nussenzweig M C. Tolerogenic dendritic cells. Annu Rev Immunol 2003: 21: 685-711.
7. Steinman R M, Nussenzweig M C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002: 99: 351-358.
8. Matsue H, Kusuhara M, Matsue K, Takashima A. Dendritic cell-based immunoregulatory strategies. Int Arch Allergy Immunol 2002: 127: 251-258.
9. Hackstein H, Morelli A E, Thomson A W. Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol 2001: 22: 437-442.
10. Khoury S J, Gallon L, Verburg R R et al. Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol 1996: 157: 3700-3705.
11. Lu L, Li W, Fu F et al. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation 1997: 64: 1808-1815.
12. Morikawa Y, Furotani M, Kuribayashi K, Matsuura N, Kakudo K. The role of antigen-presenting cells in the regulation of delayed-type hypersensitivity. I. Spleen dendritic cells. Immunology 1992: 77: 81-87.
13. Rastellini C, Lu L, Ricordi C, Starzl T E, Rao A S, Thomson A W. Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival. Transplantation 1995: 60: 1366-1370.
14. Clare-Salzler M J, Brooks J, Chai A, Van Herle K, Anderson C. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J Clin Invest 1992: 90: 741-748.
15. O'Connell P J, Li W, Wang Z, Specht S M, Logar A J, Thomson A W. Immature and mature CD8alpha+dendritic cells prolong the survival of vascularized heart allografts. J Immunol 2002: 168: 143-154.
16. Lutz M B, Suri R M, Niimi M et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000: 30: 1813-1822.
17. Griffin M D, Lutz W, Phan V A, Bachman L A, McKean D J, Kumar R. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001: 98: 6800-6805.
18. Hackstein H, Morelli A E, Larregina A T et al. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol 2001: 166: 7053-7062.
19. Morita Y, Yang J, Gupta R et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001: 107: 1275-1284.
20. Lee W C, Wan Y H, Li W et al. Enhancement of dendritic cell tolerogenicity by genetic modification using adenoviral vectors encoding cDNA for TGF beta 1. Transplant Proc 1999: 31: 1195.
21. O'Rourke R W, Kang S M, Lower J A et al. A dendritic cell line genetically modified to express CTLA4IG as a means to prolong islet allograft survival. Transplantation 2000: 69: 1440-1446.
22. Dhein J, Walczak H, Baumler C, Debatin K M, Krammer P H. Autocrine T-cell suicide mediated by APO-1/ (Fas/CD95). Nature 1995: 373: 438-441.
23. Brunner T, Mogil R J, LaFace D et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995: 373: 441-444.
24. Ju S T, Panka D J, Cui H et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995: 373: 444-448.
25. Min W P, Gorczynski R, Huang X Y et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol 2000: 164: 161-167.
26. Zhang H G, Fleck M, Kern E R et al. Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice. J Clin Invest 2000: 105: 813-821.
27. Zhang H G, Su X, Liu D et al. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J Immunol 1999: 162: 1423-1430.
28. Matsue H, Matsue K, Walters M, Okumura K, Yagita H, Takashima A. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells. Nat Med 1999: 5: 930-937.
29. Kusuhara M, Matsue K, Edelbaum D, Loftus J, Takashima A, Matsue H. Killing of naive T cells by CD95L-transfected dendritic cells (DC): in vivo study using killer DC-DC hybrids and CD4(+) T cells from DO11.10 mice. Eur J Immunol 2002: 32: 1035-1043.
30. Matsue H, Matsue K, Kusuhara M et al. Immunosuppressive properties of CD95L-transduced 'killer' hybrids created by fusing donor- and recipient-derived dendritic cells. Blood 2001: 98: 3465-3472.
31. Auchincloss H Jr, Lee R, Shea S, Markowitz J S, Grusby M J, Glimcher L H. The role of 'indirect' recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci USA 1993: 90: 3373-3377.
32. Wolfe T, Asseman C, Hughes A, Matsue H, Takashima A, von Herrath M G. Reduction of antiviral CD8 lymphocytes in vivo with dendritic cells expressing Fas ligand-increased survival of viral (lymphocytic choriomeningitis virus) central nervous system infection. J Immunol 2002: 169: 4867-4872.
33. Gould D S, Auchincloss H Jr. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 1999: 20: 77-82.
34. Josien R, Li H L, Ingulli E et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 2000: 191: 495-502.
35. Sherman L A, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol 1993: 11: 385-402.
36. Dieu MC, Vanbervliet B, Vicari A et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998: 188: 373-386.
37. Saeki H, Moore A M, Brown M J, Hwang S T. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol 1999: 162: 2472-2475.
38. MartIn-Fontecha A, Sebastiani S, Hopken U E et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003: 198: 615-621.
39. Takayama T, Nishioka Y, Lu L, Lotze M T, Tahara H, Thomson A W. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation 1998: 66: 1567-1574.
40. Takayama T, Morelli A E, Robbins P D, Tahara H, Thomson A W. Feasibility of CTLA4Ig gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro. Gene Ther 2000: 7: 1265-1273.